Roche has announced that its phase 3 IMpower130 study met its co-primary endpoints of overall survival (OS) and progression-free survival (PFS) in non-small cell lung cancer (NSCLC). The combination ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results